Plaquenil: Effective Autoimmune Disease Management
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.03 | $50.31 $50.31 (0%) | 🛒 Add to cart |
| 20 | $4.02 | $100.62 $80.50 (20%) | 🛒 Add to cart |
| 30 | $3.69 | $150.94 $110.69 (27%) | 🛒 Add to cart |
| 60 | $3.52 | $301.87 $211.31 (30%) | 🛒 Add to cart |
| 90 | $3.35 | $452.81 $301.87 (33%) | 🛒 Add to cart |
| 120 | $2.93 | $603.74 $352.18 (42%) | 🛒 Add to cart |
| 180 | $2.80 | $905.61 $503.12 (44%) | 🛒 Add to cart |
| 270 | $2.61 | $1358.42 $704.36 (48%) | 🛒 Add to cart |
| 360 | $2.40
Best per pill | $1811.22 $865.36 (52%) | 🛒 Add to cart |
| Product dosage: 400mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $7.04 | $70.44 (0%) | 🛒 Add to cart |
| 20 | $6.04 | $140.87 $120.75 (14%) | 🛒 Add to cart |
| 30 | $5.70 | $211.31 $171.06 (19%) | 🛒 Add to cart |
| 60 | $5.37 | $422.62 $321.99 (24%) | 🛒 Add to cart |
| 90 | $5.03 | $633.93 $452.81 (29%) | 🛒 Add to cart |
| 120 | $4.61 | $845.24 $553.43 (35%) | 🛒 Add to cart |
| 180 | $4.47 | $1267.86 $804.99 (37%) | 🛒 Add to cart |
| 270 | $4.29 | $1901.78 $1157.17 (39%) | 🛒 Add to cart |
| 360 | $4.05
Best per pill | $2535.71 $1459.04 (42%) | 🛒 Add to cart |
Plaquenil (hydroxychloroquine sulfate) is a disease-modifying antirheumatic drug (DMARD) widely prescribed for the management of autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus. Its immunomodulatory properties help reduce inflammation and disease activity, offering patients improved long-term control over their symptoms. By interfering with autoimmune processes at the cellular level, Plaquenil supports sustained remission and enhances quality of life. Proper usage under medical supervision is essential to maximize therapeutic benefits while minimizing risks.
Features
- Contains hydroxychloroquine sulfate as the active ingredient
- Available in 200 mg oral tablets
- Long half-life allowing for once or twice daily dosing
- Well-established safety profile with decades of clinical use
- Manufactured under strict pharmaceutical quality standards
Benefits
- Reduces joint pain, swelling, and stiffness in rheumatoid arthritis
- Decreases frequency and severity of lupus flares
- Helps prevent long-term joint damage and disease progression
- May improve skin manifestations in cutaneous lupus
- Can be used in combination with other DMARDs for enhanced efficacy
- Generally well-tolerated with proper monitoring
Common use
Plaquenil is primarily indicated for the treatment of rheumatoid arthritis, systemic lupus erythematosus, and discoid lupus erythematosus. It is also used off-label for other autoimmune conditions including Sjögren’s syndrome, palindromic rheumatism, and certain dermatological conditions. The medication works by modulating immune system activity, though its exact mechanism of action continues to be studied. Clinical response typically develops gradually over several weeks to months of continuous therapy.
Dosage and direction
The recommended adult dosage for rheumatoid arthritis is 400-600 mg daily initially, followed by a maintenance dose of 200-400 mg daily. For lupus erythematosus, doses typically range from 200-400 mg daily. Administration should be with food or milk to minimize gastrointestinal upset. Dosage is based on ideal body weight, not to exceed 6.5 mg/kg of actual body weight. Regular ophthalmologic examinations are required due to potential retinal toxicity.
Precautions
Patients should undergo baseline and annual ophthalmologic examinations including visual field testing and spectral domain optical coherence tomography. Renal and hepatic function should be monitored periodically. Use with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to hemolysis risk. May exacerbate psoriasis and porphyria. Caution advised in elderly patients and those with hepatic or renal impairment.
Contraindications
Hypersensitivity to hydroxychloroquine, 4-aminoquinoline compounds, or any component of the formulation. Contraindicated in patients with pre-existing retinal field changes attributable to 4-aminoquinoline compounds. Not recommended in patients with known porphyria. Avoid use in children except for juvenile idiopathic arthritis under specialist supervision.
Possible side effects
Common side effects include gastrointestinal disturbances (nausea, diarrhea, abdominal cramps), headache, dizziness, and skin eruptions. Ocular effects may include accommodation difficulties, corneal deposits (usually reversible), and rarely irreversible retinopathy. Less frequent adverse reactions include neuromuscular effects, hematologic changes, and cardiovascular effects. Psychiatric reactions including mood changes have been reported.
Drug interaction
Plaquenil may enhance the effects of digoxin and insulin. Concomitant use with other hepatotoxic drugs may increase risk of liver damage. Antacids and kaolin may reduce absorption. May increase plasma levels of cyclosporine. Caution with drugs that prolong QT interval. May enhance effects of other DMARDs when used in combination therapy.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent therapeutic levels. Contact healthcare provider if multiple doses are missed for guidance on resumption.
Overdose
Overdose can be fatal, with symptoms including headache, drowsiness, visual disturbances, cardiovascular collapse, and convulsions. Children are particularly susceptible. Treatment is symptomatic and supportive, with immediate gastric lavage if ingestion occurred within 1 hour. Respiratory support and cardiovascular monitoring may be necessary. There is no specific antidote.
Storage
Store at room temperature (20-25°C/68-77°F) in original container. Protect from light and moisture. Keep out of reach of children and pets. Do not use if tablets show signs of deterioration or are beyond expiration date. Properly dispose of unused medication according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any treatment regimen. Individual response to medication may vary. Proper medical supervision is essential throughout treatment.
Reviews
Clinical studies demonstrate Plaquenil’s efficacy in reducing disease activity scores in rheumatoid arthritis and decreasing lupus flare frequency. Many patients report significant improvement in quality of life and functional capacity. Ophthalmologic monitoring remains crucial for long-term safety. The medication is generally well-tolerated when used as directed under appropriate medical supervision.